Treatment of pulmonary neuroendocrine tumours: State of the art and future developments
Cesare Gridelli(Azienda Ospedaliera S.Giuseppe Moscati), Ferdinando Riccardi(Ospedale Antonio Cardarelli), Paolo Maione(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Antônio Rossi(Università Campus Bio-Medico), Giuseppe Grimaldi(Policlinico Umberto I), Franco Vito Piantedosi, Roberto Bianco(Federico II University Hospital), Alessandro Morabito(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Bruno Daniele(Azienda Ospedaliera G.Rummo), Raffaele Costanzo, Giuseppe Airoma, Giovanni De Chiara(Azienda Ospedaliera S.Giuseppe Moscati), Luciana Irtelli(Ospedale SS. Annunziata)
Cited by 69
Related Papers
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial
|Journal of Clinical Oncology|2019|1.8k
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial
|The Lancet Oncology|2019|1.7k
Non-small-cell lung cancer
|Nature Reviews Disease Primers|2015|1.1k
Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|1.1k